Related Experiment Video
Updated: Jul 12, 2026
14:25
Synthesis of a Deuterated Standard for the Quantification of 2-Arachidonoylglycerol in Caenorhabditis elegans
Published on: September 21, 2019
Genetic polymorphisms of the endocannabinoid system
Allison G Norrod1, Robyn A Puffenbarger
1Bridgewater College, 402 E. College Street, Bridgewater, VA 22812-1599, USA.
Chemistry & Biodiversity
|August 23, 2007
Summary
Genetic variations in the endocannabinoid system are linked to various diseases. This review focuses on polymorphisms associated with mental disorders, substance abuse, and metabolism.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- The endocannabinoid system plays a crucial role in physiological processes.
- Dysregulation of this system is implicated in neurological and metabolic disorders.
- Genetic variations within the endocannabinoid system are increasingly recognized as significant.
Purpose of the Study:
- To review identified genetic polymorphisms within the endocannabinoid system.
- To highlight polymorphisms associated with specific conditions, including mental disorders and substance abuse.
- To examine the link between endocannabinoid system genetics and energy metabolism.
Main Methods:
- Literature review of genetic polymorphisms in the endocannabinoid system.
- Focus on studies investigating associations with disease and behavioral phenotypes.
- Synthesis of current knowledge on relevant genetic variations.
Main Results:
- Numerous genetic polymorphisms in endocannabinoid system genes and proteins have been identified.
- Specific polymorphisms are linked to conditions such as schizophrenia, other mental disorders, and drug/alcohol abuse.
- Evidence suggests a role for these polymorphisms in energy metabolism regulation.
Conclusions:
- Genetic polymorphisms in the endocannabinoid system are relevant to a range of diseases.
- Further research into these genetic variations may offer insights into disease mechanisms and therapeutic targets.
- Understanding these polymorphisms is crucial for fields including psychiatry, neurology, and metabolic research.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...